Clinical and Experimental Nephrology

, Volume 17, Issue 2, pp 275–283

Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients

  • Jungmin Son
  • Soo Bong Lee
  • Dong Won Lee
  • Il Young Kim
  • Su Jin Lee
  • Sun Min Lee
  • Sang Heon Song
  • Eun Young Seong
  • Ihm Soo Kwak
Original Article

DOI: 10.1007/s10157-012-0696-1

Cite this article as:
Son, J., Lee, S.B., Lee, D.W. et al. Clin Exp Nephrol (2013) 17: 275. doi:10.1007/s10157-012-0696-1

Abstract

Background

In response to the pandemic 2009 A/H1N1 virus, monovalent MF59-adjuvanted vaccines were prepared. Recently, single 3.75-μg doses of MF59-adjuvanted vaccines have shown good immunogenicity in young adults. However, the immunogenicity of these vaccines has not been evaluated in dialysis patients.

Methods

Dialysis patients received a single 3.75-μg dose of MF59-adjuvanted vaccine by intramuscular injection. For immunogenicity assays, serum samples were obtained before vaccination and 28 days after vaccination. All sera were tested by hemagglutination inhibition assays.

Results

Overall, 48 hemodialysis (HD) patients and 34 peritoneal dialysis (PD) patients were included in immunogenicity analysis. In HD patients, geometric mean titers (GMTs) were significantly increased compared with baseline GMTs in both young (aged 18–60 years) and elderly (aged ≥60 years) patients (51.2 ± 51.4 vs. 14.1 ± 20.7 in young patients, P = 0.012; 37.9 ± 73.9 vs. 6.8 ± 8.0 in elderly patients, P = 0.018, respectively). The rates of seroprotection and seroconversion were 27.6 and 17.2 % in young patients and 31.6 and 26.3 % in elderly patients, respectively. Among PD patients, GMTs were increased only in young patients (39.8 ± 51.4 vs. 6.8 ± 5.0, P = 0.001). The rates of seroprotection and seroconversion were 36.0 and 36.0 % in young patients and 11.1 and 0.0 % in elderly patients, respectively.

Conclusion

A single 3.75-μg dose of MF59-adjuvanted vaccine was suboptimal to elicit protective antibody response in dialysis patients. Antibody responses against vaccine were compromised especially in elderly PD patients. Trials of different vaccination protocols such as a two-dose schedule or a higher hemagglutinin antigen dose of MF59-adjuvanted vaccine are necessary for improving antibody response in dialysis patients.

Keywords

AdjuvantDialysisEnd-stage renal diseaseImmunogenicityInfluenza A/H1N1Vaccination

Copyright information

© Japanese Society of Nephrology 2012

Authors and Affiliations

  • Jungmin Son
    • 1
    • 4
  • Soo Bong Lee
    • 1
    • 4
  • Dong Won Lee
    • 1
    • 4
  • Il Young Kim
    • 1
    • 4
  • Su Jin Lee
    • 2
    • 4
  • Sun Min Lee
    • 3
    • 4
  • Sang Heon Song
    • 1
    • 5
  • Eun Young Seong
    • 1
    • 5
  • Ihm Soo Kwak
    • 1
    • 5
  1. 1.Division of Nephrology, Department of Internal MedicinePusan National University School of MedicineYangsanSouth Korea
  2. 2.Division of Infectious Disease, Department of Internal MedicinePusan National University School of MedicineYangsanSouth Korea
  3. 3.Department of Laboratory MedicinePusan National University School of MedicineYangsanSouth Korea
  4. 4.Research Institute for Convergence of Biomedical Science and TechnologyPusan National University Yangsan HospitalYangsanSouth Korea
  5. 5.Medical Research InstitutePusan National University HospitalBusanSouth Korea